Q3 2025 Hansa Biopharma AB Earnings Call Transcript

Oct 30, 2025 / 12:00 PM GMT

Release Date Price: $4.58

Transcript

Key Points

Positve

Hansa Biopharma AB (HNSBF) reported a successful outcome of their phase 3 trial with a strong p-value of 0.0001, indicating significant efficacy.
The company has strengthened its cash position through two successful equity raises and debt restructuring.
Hansa Biopharma AB (HNSBF) has secured national reimbursement in 21 European and international markets, covering over 90% of the European population.
The US market presents a significant opportunity with a large unmet need for desensitization therapy in highly sensitized kidney transplant patients.
The company has a well-researched and structured launch plan for the US market, with strong market analytics capabilities and experienced team members.

Negative

Sales in Germany were negatively impacted due to the pause in the Eurotransplant prioritized program, resulting in zero sales in Q3.
The Spanish market faced challenges due to regional dynamics, particularly in Catalonia and Andalusia, affecting sales performance.
Total revenue for Q3 2025 was 37% below the same period a year ago, reflecting a decline in contract revenues and product sales.
The European market faces structural barriers, including complex reimbursement processes and fragmented organ allocation systems.
The company reported an operating loss of approximately 147.6 million SEK for Q3 2025, which was 20.8% unfavorable compared to the previous year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HNSA.ST - Hansa Biopharma AB
Q3 2025 Hansa Biopharma AB Earnings Call
Oct 30, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Pharma quarter 3 2025 results conference call. All participants will be in listen-only mode. Should you need assistance, please signal conference specialist by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press 1 on your touchtone phone. To withdraw your question, please press 2. Please note this event is being recorded.

I would now like to turn the conference over to Honza BioPharma CEO Renee Aguiar Lukander. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.